Advertisement

Treatment of the Portal Vein Thrombosis

  • Shigehiro Kokubu
Chapter

Abstract

The treatment of portal vein thrombosis is performed based on a symptomatic acute clot or an asymptomatic chronic clot and further depends on whether the underlying disease is cirrhosis or not. In all cirrhotic cases, attention should be paid to hemorrhagic complications. In particular, it is necessary to perform appropriate prophylactic endoscopic injection sclerotherapy/endoscopic variceal ligation in complicated case of esophagogastric varices. In recent years the use of antithrombin-III (AT-III) preparations and danaparoid sodium have increased in place of heparin, urokinase, and warfarin for the treatment of portal vein thrombosis. Based on the fact that antithrombotic action (fibrinolysis) has been reported even with AT-III alone, and that AT-III doesn’t affect the bleeding tendency, it is safe and effective to use it for portal vein thrombosis with esophagogastric varices. And danaparoid sodium has higher anti-factor Xa activity than heparin. In addition, the usefulness of danaparoid with less risk of bleeding has also been reported.

Keywords

AT-III preparations Danaparoid sodium Hemorrhagic complications D-dimer FDP 

References

  1. 1.
    DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study liver Disease. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.CrossRefGoogle Scholar
  2. 2.
    Tsochatzis EA, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31:336–74.CrossRefGoogle Scholar
  3. 3.
    Valla DC. Thrombosis and anticoagulation in liver disease. Hepatology. 2008;47:1384–93.CrossRefGoogle Scholar
  4. 4.
    Amitrano L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40:736–41.CrossRefGoogle Scholar
  5. 5.
    Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patient with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:776–83.CrossRefGoogle Scholar
  6. 6.
    Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44:448–51.PubMedGoogle Scholar
  7. 7.
    Takada M, Kokubu S. Clinical pathophysiology and treatment of portal hypertension. TreatmentUpdate. 1999;81:235–42.Google Scholar
  8. 8.
    Schpper HG, Ten JW. Antithrombin III transfusion in patient with hepatic cirrhosis. Br J Haematol. 1982;52:25–33.CrossRefGoogle Scholar
  9. 9.
    Kawanaka H, Akahoshi T, Kinjo N, et al. Impact of antithrombin III concentrates on portal vein thrombus after splenectomy in patients with liver cirrhosis and hypersplenism. Ann Surg. 2010;251:76–83.CrossRefGoogle Scholar
  10. 10.
    Kawanaka H, Akahoshi T, Itoh S, et al. Optimizing risk stratification in portal vein thrombus after splenectomy and prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension. J Am Coll Surg. 2014;219:865–74.Google Scholar
  11. 11.
    John BV, Konjeti R, Aggarwal A, et al. Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis. Ann Hepatol. 2013;12:952–8.PubMedGoogle Scholar
  12. 12.
    Shuto T, Yazaki Y, Sugawara K. In use experience of danaparoid sodium for the portal vein thrombosis. J Japan Portal Hypertens. 2005;11(2):171–3.Google Scholar
  13. 13.
    Kokubu S. Diagnosis, pathogenesis and latest therapy in portal hypertension. J Japan Gastroenterol. 2008;105:1588–96.Google Scholar
  14. 14.
    Naeshiro N, Aikata H, Chayama K, et al. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombus in patient with liver cirrhosis. Hepatorol Res. 2015;45:656–62.CrossRefGoogle Scholar
  15. 15.
    Hidaka H, Kokubu S, Satou T, Katsushima S, et al. Antithrombin III administration for portal vein thrombosis in patient with liver disease; a randomized double blind controlled trial. Hepatol Res. 2018;48(3):E107–16.  https://doi.org/10.1111/hepr.12934.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Shigehiro Kokubu
    • 1
  1. 1.Shin-yurigaoka General Hospital Institute for Liver Disease Minimal Invasive Treatment, Endoscopic CenterKawasakiJapan

Personalised recommendations